Growth of Antibody-Drug Conjugates (ADC’s): The present and future opportunities
Tracks
Track 1
| Thursday, October 31, 2024 |
| 1:30 PM - 2:15 PM |
Details
Antibody-Drug Conjugates (ADCs) are revolutionising cancer treatment by combining targeted precision with powerful medication. Currently, successful ADCs are making a real difference in fighting cancers with fewer side effects compared to traditional therapies. The technology behind ADCs is advancing rapidly, with improvements in how these drugs are delivered and how effectively they work. Looking ahead, there are exciting opportunities to expand ADCs to treat a wider range of therapeutics for even better results. This panel session will explore the current global landscape in ADCs and discuss the opportunities that this ground-breaking innovation presents.
Speaker
Dr. Christina Frenzel
Medical Director
AstraZeneca
Chair
Dr Jeremy Paull
VP Development & Regulatory Affairs
Starpharma
Panellist
Dr. Birgit Reitmaier
Executive Director, Head of BD Asia Pacific Biopharma, Global Business Development and Alliance Management
Merck Pte. Ltd
Panellist
Dr. Peter Savas
Medical Oncologist and Postdoctoral Researcher
Peter MacCallum Cancer Centre
Panellist
